Clinical meaning
Advanced RA management requires the NP to apply treat-to-target (T2T) principles with DAS28 scoring for disease activity assessment. The DAS28 incorporates tender joint count (28 joints), swollen joint count, ESR or CRP, and patient global assessment. Target: DAS28 <2.6 (remission) or <3.2 (low disease activity). Treatment algorithm: start methotrexate 15 mg/week escalating to 25 mg/week within 8 weeks; if target not reached by 3-6 months, add or switch to biologic DMARD. Biologic selection is guided by mechanism and comorbidities: TNF inhibitors (etanercept, adalimumab, infliximab) are first-line biologics — avoid in CHF (NYHA III-IV), active hepatitis B, or demyelinating disease. IL-6 inhibitors (tocilizumab) — monitor lipids and avoid with diverticulitis risk. JAK inhibitors (tofacitinib, baricitinib) are oral targeted synthetic DMARDs — FDA black box warning for increased risk of serious infections, malignancy, thromboembolism, and cardiovascular events vs. TNF inhibitors. T-cell costimulation inhibitor (abatacept) — preferred with ILD. B-cell depletion (rituximab) — reserved for RF/anti-CCP positive patients failing TNF inhibitors. Combination DMARD therapy (methotrexate + leflunomide or methotrexate + sulfasalazine + hydroxychloroquine 'triple therapy') is an alternative to biologics. Monitoring includes regular...